VYNE THERAPEUTICS INC.

(VYNE)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
0.4540 USD   +3.89%
06/17VYNE Therapeutics Completes Enrollment in Trial of Atopic Dermatitis Treatment
MT
06/17VYNE THERAPEUTICS : Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis - Form 8-K
PU
06/17VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HC Wainwright Assumes VYNE Therapeutics at Buy with $7 Price Target

12/06/2021 | 10:17am EDT


© MT Newswires 2021
All news about VYNE THERAPEUTICS INC.
06/17VYNE Therapeutics Completes Enrollment in Trial of Atopic Dermatitis Treatment
MT
06/17VYNE THERAPEUTICS : Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of ..
PU
06/17VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
06/17VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of..
AQ
06/17VYNE Therapeutics Inc. Completes Enrollment in Phase 2A Trial of FMX 114 for the Treatm..
CI
05/18VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
AQ
05/17VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
05/17TRANSCRIPT : VYNE Therapeutics Inc. - Special Call
CI
05/12VYNE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Loss $-0.14
MT
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 0,43 M - -
Net income 2022 -37,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,78x
Yield 2022 -
Capitalization 26,3 M 26,3 M -
Capi. / Sales 2022 60,7x
Capi. / Sales 2023 105x
Nbr of Employees 28
Free-Float 98,5%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 0,45 $
Average target price 6,00 $
Spread / Average Target 1 222%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-55.49%26
JOHNSON & JOHNSON4.94%468 758
ELI LILLY AND COMPANY17.55%294 514
PFIZER, INC.-11.41%289 747
ABBVIE INC.13.69%272 011
ROCHE HOLDING AG-15.85%269 131